Ipatasertib联合内分泌治疗及CDK4/6抑制剂在HR+/HER2-转移性乳腺癌中的安全性与抗肿瘤活性(TAKTIC):单中心、开放标签、1b期试验
TAKTIC是一项单中心、开放标签的1b期试验,纳入77例HR+/HER2-转移性乳腺癌患者(66例既往接受过CDK4/6抑制剂),评估ipatasertib联合氟维司群或芳香化酶抑制剂、以及联合氟维司群+哌柏西利的安全性。
要点
- 推荐2期剂量:ipatasertib 400 mg d1-21+哌柏西利100 mg d8-28+氟维司群500 mg。
- 常见3-4级不良事件:中性粒细胞减少39%、白细胞减少19%、腹泻18%。
核心结论
- 氟维司群+ipatasertib+哌柏西利在重度经治HR+/HER2-转移性乳腺癌中显示初步临床活性及预期不良事件,值得在CDK4/6抑制剂难治人群进一步评估。
研究设计与样本
- 单中心、开放标签、1b期试验,在马萨诸塞州总医院开展,纳入77例HR+/HER2-局部晚期不可切除或转移性乳腺癌女性患者。
- 患者分入ipatasertib+氟维司群组(19例)、ipatasertib+芳香化酶抑制剂组(16例)、ipatasertib+氟维司群+哌柏西利组(42例,含3+3剂量递增)。
- 主要终点为安全性,关键次要终点为无进展生存期;安全性分析纳入所有接受至少一剂ipatasertib的患者,PFS评估所有入组参与者。
主要发现
- 与研究治疗相关的严重不良事件:ipatasertib+氟维司群+哌柏西利组7例(17%),ipatasertib+氟维司群组1例(5%),涉及中性粒细胞减少、白细胞减少、血小板减少和高血糖。
- 常见(>5%)治疗相关3-4级不良事件:中性粒细胞减少30/77(39%)、白细胞减少15/77(19%)、腹泻14/77(18%)、皮疹7/77(9%)、贫血4/77(5%)、淋巴细胞减少3/77(4%)。
- 研究期间4例死亡:ipatasertib+氟维司群组1例可能治疗相关(5级高血糖),ipatasertib+氟维司群+哌柏西利组2例感染和1例肺部并发症,判定与研究治疗无关。
关键数值与推荐
- 推荐2期剂量为ipatasertib 400 mg d1-21联合哌柏西利100 mg d8-28及标准氟维司群500 mg。
- 入组条件:>18岁女性,活检证实HR+/HER2-局部晚期不可切除或转移性乳腺癌,ECOG 0-2,至少一线转移性疾病治疗后进展,有可测量病灶或骨病灶。
- 剂量递增组从哌柏西利推荐剂量125 mg(d1-21)和ipatasertib最低剂量200 mg(d1-21)开始,采用标准3+3设计。
临床怎么用
- 对于既往CDK4/6抑制剂治疗后进展的HR+/HER2-转移性乳腺癌,可考虑ipatasertib联合内分泌治疗及CDK4/6抑制剂,但需密切监测中性粒细胞减少、腹泻和高血糖。
- 推荐2期剂量为ipatasertib 400 mg d1-21+哌柏西利100 mg d8-28+氟维司群500 mg,该方案需进一步在CDK4/6抑制剂难治人群中验证。
局限性
- 单中心、开放标签、1b期试验,样本量有限(77例),结果需更大规模研究验证。
- 患者以白人为主(75/77,97%),种族多样性有限。
- 研究期间出现4例死亡,其中1例可能治疗相关(5级高血糖),需关注安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: PI3K/AKT pathway activation is implicated in CDK4/6 inhibitor resistance. The use of AKT inhibition with continued CDK4/6 blockade after CDK4/6 inhibitor resistance remains unexplored. We evaluated the safety of ipatasertib and an antioestrogen with or without palbociclib in patients with treatment refractory HR+/HER2- metastatic breast cancer. METHODS: This single-centre, open-label, phase 1b trial was conducted at the Massachusetts General Hospital (Boston, MA, USA). Eligible patients were women older than 18 years with biopsy proven HR+/HER2- locally advanced, unresectable, or metastatic breast cancer; an Eastern Cooperative Oncology Group performance status of 0-2; disease progression on at least one previous therapy for metastatic disease; and measurable disease or bone lesions. Patients received 400 mg oral ipatasertib with standard 500 mg intramuscular fulvestrant dosing (ipatasertib and fulvestrant group) or with an aromatase inhibitor (oral anastrozole 1 mg per day, exemestane 25 mg per day, or letrozole 2·5 mg per day; ipatasertib and aromatase inhibitor group) on days 1-28 of each cycle. The ipatasertib and fulvestrant plus palbociclib group included a dose-escalation phase with patients assigned sequentially to escalating doses of ipatasertib and palbociclib using a standard 3 + 3 design starting at the recommended dose of palbociclib (125 mg on days 1-21) and the lowest dose of ipatasertib (200 mg on days 1-21). The primary endpoint was safety and progression-free survival was a key secondary endpoint. Safety was analysed in all patients who received at least one dose of ipatasertib and progression-free survival was assessed in all enrolled participants. This study is registered with ClinicalTrials.gov, NCT03959891 (active, not recruiting). FINDINGS: Between June 5, 2019, and Feb 16, 2022, 77 patients were enrolled (19 assigned to ipatasertib and fulvestrant, 16 to ipatasertib and aromatase inhibitor, and 42 to ipatasertib and fulvestrant plus palbociclib). All patients were female (77 [100%]); 75 were White (97%) and two (3%) were Asian. The median age was 62 years (range 32-88) and 66 (86%) of 77 patients received previous CDK4/6 inhibitor (median number of previous lines was 3 [range 1-13]). The median follow-up was 12·5 months (IQR 7·6-19·7). The recommended phase 2 dose was established at 400 mg ipatasertib on days 1-21 with 100 mg palbociclib on days 8-28 and standard fulvestrant 500 mg. Median progression-free survival was 5·5 months (95% CI 3·8-7·4). Serious adverse events related to study treatment occurred in seven (17%) patients in the ipatasertib and fulvestrant plus palbociclib group and one (5%) in the ipatasertib and fulvestrant group, which were related to neutropenia, leukopenia, thrombocytopenia, and hyperglycaemia. Common grade 3-4 adverse events related to study treatment (occurring in >5% of patients) were neutropenia (30 [39%] of 77), leukopenia (15 [19%]), diarrhoea (14 [18%]), rash (seven [9%]), lymphopenia (three [4%]), and anaemia (four [5%]). Four deaths occurred during the study (one possibly treatment-related due to grade 5 hyperglycaemia in the ipatasertib and fulvestrant group and two due to infectious issues and one due to pulmonary complications in the ipatasertib and fulvestrant plus palbociclib group), deemed unrelated to study treatment. INTERPRETATION: The combination of fulvestrant, ipatasertib, and palbociclib showed preliminary signs of clinical activity and showed expected adverse events in heavily pretreated patients with HR+/HER2- metastatic breast cancer, warranting further evaluation in those with CDK4/6 inhibitor-refractory disease. FUNDING: Genentech, Howard Hughes Medical Institute, National Foundation for Cancer Research, and Breast Cancer Research Foundation.
引用
- Wander SA, Lloyd MR, Keenan JC, et al. Safety and antitumour activity of ipatasertib combined with endocrine therapy and a CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer (TAKTIC): a single-centre, open-label, phase 1b trial. Lancet Oncol. 2026. PMID: 42061370. doi:10.1016/S1470-2045(26)00059-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。